Sign in
KTRA Stock Price, Chart, Stats & News
Kintara Therapeutics, Inc.
Save
Kintara Therapeutics, Inc. (KTRA) does not currently pay a dividend.
11.99M
Market cap
–
Current P/E
–
Forward P/E
KTRA chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -99.13% |
ROE | -213.26% |
D/E | 0.01x |
Interest coverage ratio | – |
KTRA valuation
P/E | – |
P/S | – |
P/B | 0.65x |
P/CF | -0.46x |
P/FCF | -0.50x |
P/OCF | -0.46x |
PEG | -0.01x |
EV multiple | -2.07x |
About
Kintara Therapeutics, Inc. operates as a clinical-stage biotechnology firm, dedicated to pioneering and commercializing anti-cancer treatments for patients. Central to its pipeline are two compounds nearing Phase III trials. One, VAL-083, is a DNA-targeting agent developed to combat drug-resistant solid tumors, including challenging conditions like glioblastoma multiforme, alongside other solid tumor types such as ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma.
Similar securities
Based on sector and market capitalization
Report issue